Men who have had or will have a prostatectomy and are at high-risk of recurrence may be eligible for this study.
A research study at the Medical University of South Carolina is currently enrolling prostate cancer patients to a study of PSA-Targeted Immunotherapy product. The purpose of this study is to see how well this investigational product works in stopping prostate cancer from coming back or relapsing. This study consists of seven vaccine injections over the course of six months. Eligible patients must have had or are planning to have a prostatectomy within four months of enrollment and be considered high-risk for recurrence of disease. Not sure if you are at high-risk? Please contact Dr. Michael Lilly at email@example.com or Mike Wheeler at firstname.lastname@example.org to discuss your eligibility for study #102377.
IRB# Pro00054476. Date approved: 10/25/2016.
Learn more about clinical trials at Hollings Cancer Center.